Appendix Table 5.
Head-to-Head Comparisons of Sensitivity of QuantiFERON-TB (QFT) Gold versus T-SPOT.TB among Patients with Active Tuberculosis (TB)
| Study, Year (Reference) |
Industry Supported?* |
Sample | Setting | Patients with Active (Culture-Confirmed) TB, n (%) | Sensitivity† | Difference between T-SPOT.TB and QFT Gold Sensitivity, percentage points | |
|---|---|---|---|---|---|---|---|
| Patients with Positive QFT Gold Result, n (%) | Patients with Positive T-SPOT.TB Result, n (%) | ||||||
| Lee et al., 2006 (11) | Yes | Predominantly adults | South Korea | 87 (63) | 61 (70)‡ | 83 (95) | 25 |
| Ferrara et al., 2006 (12) | Yes | Predominantly adults | Italy | 24 (NR) | 17 (71)‡ | 20 (83) | 12 |
| Goletti et al., 2006 (13) | Yes | Predominantly adults | Italy | 23 (100) | 19 (83)‡ | 21 (91) | 8 |
| Kang et al., 2007 (17) | Yes | Adults | South Korea | 67 (100) | 58 (87)‡ | 59 (92) | 5 |
| Soysal et al., 2008 (19) | NR | Predominantly adults | Turkey | 100 (100) | 77 (77)‡ | 80 (80) | 3 |
| Domínguez et al., 2008 (23) | Yes | Adults and children§ | Spain | 42 (NR) | 33 (79)|| | 36 (86) | 7 |
| Detjen et al., 2007 (25) | No | Children | Germany | 28 (100) | 26 (93)|| | 26 (93) | 0 |
NR = not reported.
*
“Industry support” refers to any industry involvement or support (e.g., sponsorship, donation of test kits, participation in advisory boards, and involvement of test developers or ownership of patents).
†
Indeterminate results were not excluded in calculating sensitivity estimates.
‡
QFT Gold.
§
Children formed 27% of the sample.
||
QFT Gold In-Tube.